Immunohistochemical evaluation of thymidylate synthase (TS) and p16INK4a in advanced colorectal cancer: Implication of TS expression in 5-FU-based adjuvant chemotherapy

Japanese Journal of Clinical Oncology

Volumn 34, Issue 10, 2004, Pages 594-601

  Kamoshida, Shingo ^a   Matsuoka, Hiroshi ^a   Ishikawa, Taro ^a   Maeda, Kotaro ^a   Shimomura, Ryoichi ^a   Inada, Ken Ichi ^a   Tsutsumi, Yutaka ^a  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

5 fluorouracil; Adjuvant chemotherapy; Colorectal cancer; p16INK4a; Thymidylate synthase

Indexed keywords

CARMOFUR; FLUOROURACIL; FOLINIC ACID; FORMALDEHYDE; MITOMYCIN C; PARAFFIN; PROTEIN P16INK4A; THYMIDYLATE SYNTHASE; UFT; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; TEGAFUR; UFT(R) DRUG; URACIL;

ADJUVANT CHEMOTHERAPY; ADULT; ADVANCED CANCER; AGED; ANTIGENICITY; ARTICLE; CANCER CLASSIFICATION; CANCER RECURRENCE; CANCER RESEARCH; CANCER STAGING; CLINICAL STUDY; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PROGNOSIS; PROTEIN EXPRESSION; STATISTICAL ANALYSIS; SURVIVAL RATE; BIOSYNTHESIS; CANCER INVASION; COLON TUMOR; DRUG COMBINATION; METABOLISM; MIDDLE AGED; PATHOLOGY; RECTUM TUMOR;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DRUG COMBINATIONS; FEMALE; FLUOROURACIL; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; POSTOPERATIVE PERIOD; RECTAL NEOPLASMS; TEGAFUR; THYMIDYLATE SYNTHASE; URACIL;

EID: 16644388108     PISSN: 03682811     EISSN: None     Source Type: Journal    
DOI: 10.1093/jjco/hyh113     Document Type: Article

References (39)

1. McLeod HL, Murray GI. Tumour markers of prognosis in colorectal cancer. Br J Cancer1999;79:191-203.
2. Advanced colorectal cancer meta-analysis project. Modulation of fluorouracil by leucovorin in patients with colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992;10:896-903.
3. Pinedo HM, Peters GFJ. Fluorouracil: biochemistry and pharmacology. J Clin Oncol 1988;6:1653-64.
4. Beck A, Etienne MC. Cheradame S, Fischel JL, Formento P, Renee N et al. A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil. Eur J Cancer 1994;30A: 1517-22.
5. Peters GJ, van der Wilt CL, van Groeningen CJ. Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase.Eur J Cancer 1994;30A: 1408-11.
6. Edler D, Blomgre H, Allegra CI, Johnston PG, Lagerstedt U, Magnusson I et al. Immunohistochemical determination of thymidylate synthase in colorectal cancer. Methodological studies. Eur J Cancer 1997; 33: 2278-81.
7. Findlay MPN, Cunningham D, Morgan G, Clinton S, Hardcastle A. Aherne GW. Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy. Br J Cancer 1997;75:903-9.
8. Paradiso A, Simone G, Petroni S, Leone B, Vallejo C, Lacava J et al. Thymidylate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients. Br J Cancer 2000;82:560-7.
9. Aschele C; Debernardis D, Tunesi G, Maley F, Sobrero A. Thymidylate synthase protein expression in primary colorectal cancer compared with the corresponding distant metastases and relationship with the clinical response to 5-fluorouracil. Clin Cancer Res 2000;6:4797-802.
10. Berglund A, Edler D, Molin D. Nordlinder H. Graf W, Glimelius B. Thymidylate synthase and p53 expression in primary tumor do not predict chemotherapy outcome in metastatic colorectal carcinoma. Anticancer Res 2002;22:3653-60.
11. Edler D, Glimelius B, Hallström M, Jakobsen A, Johnston PG, Magnusson I et al. Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. J Clin Oncol2002:20:1721-8.
12. Allegra CJ, Parr AL. Wold LE. Mahoney MR, Sargent DJ, Johnston P et al. Investigation of the prognostic and predictive value of thymidylate synthase, p53. and Ki-67 in patients with locally advanced colon cancer. J Clin Oncol 2002;20:1735-43.
13. Leichman CG. Lenz HJ, Leichman L. Danenberg K, Baranda J, Groshen S et al. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 1997;15:3223-9.
14. Aschele C, Debernardis D, Casazza S, Antonelli G, Tunesi G, Baldo C et al. Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy. J Clin Oncol 1999; 17:1760-70.
15. Cascinu S, Aschele C, Barni S, Debemardis D, Baldo C, Tunesi G et al. Thymidylate synthase protein expression in advanced colon cancer: correlation with the site of metastasis and the clinical response to leucovorin-modulated bolus 5-fluorouracil. Clin Cancer Res 1999;5:1996-9.
16. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993; 366: 704-7.
17. 1 control. Cancer Res 1995;55:4818-23.
18. Koh J, Enders GH, Dynlacht BD, Harlow E. Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature 1995;375: 506-10.
19. Reddel RR. Genes involved in the control of cellular proliferative potential. Ann NY Acad Sci 1998;854:8-19.
20. Sherr CJ. The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol 2001;2:731-7.
21. INK4a in anatomic and gender-specific subtypes of sporadic colorectal cancer. Cancer Epidemiol Biomarkers Prev 1999;8:501-6.
22. Esteller M, Gonzalez S, Risques RA, Marcuello E, Mangues R, Germa JR et al. K-tas and p16 aberrations confer poor prognosis in human colorectal cancer. J Clin Oncol2001; 19:299-304.
23. Trzeciak L, Hennig E, Kolodziejski J. Nowacki M. Ostrowski J. Mutations, methylation and expression of CDKN2a/p16 gene in colorectal cancer and normal colonic mucosa. Cancer Lett 2001; 163:17-23.
24. Hibi K, Nakayama H, Koike M, Kasai Y, Ito K, Akiyama S et al. Colorectal cancers with both p16 and p 14 methylation show invasive characteristics. Jpn J Cancer Res 2002:93:883-7.
25. Zhao P, Hu Y-C, Talbot IC. Expressing pattems of p 16 and CDK4 correlated to prognosis in colorectal carcinoma. World J Gastroenterol 2003;9: 2202-6.
26. L protein in colorectal cancer with preoperative peroral chemotherapy: TS as marker of unresponsiveness to 5-fluorouracil. Ann Cancer Res Ther 2003;11:73-94.
27. INK4a-mediated cellular arrest as an indicator of chemosensitivity to 5-fluorouracil. Pathol Intern 2004;54: 564-75.
28. Sobin LH, Wittekind Ch, editors. UICC: TNM Classification of Malignant Tumours, 5th edn. New York: John Wiley, 1997.
29. Kamoshida S, Matsuoka H, Matsuyama A, Shimomura R, Matuta M, Tsutsumi Y. Reproducible and reliable immunohistochemical demonstration of thymidylate synthase in formalin-fixed, paraffin-embedded sections: application of antigen retrieval in ethylenediaminetetraacetic acid solution. Acta Histochem Cytochem 2003;36:115-8.
30. Midgley RS, Kerr DJ. Adjuvant treatment of colorectal cancer. Cancer Treat Rev 1997;23:135-52.
31. Cascinu S, Graziano F, Valentini M, Catalano V, Giordani P, Staccioli MP et al. Vascular endothelial growth factor expression, S-phase fraction and thymidylate synthase quantitation in node-positive colon cancer: relationships with tumor recurrence and resistance to adjuvant chemothempy. Ann Oncol 2001; 12:239-44.
32. Marsh S, McKay JA, Curran S, Murray GI, Cassidy J, McLeod HL. Primary colorectal tumour is not an accurate predictor of thymidylate synthase in lymph node metastasis. Oncol Rep 2002;9:231-4.
33. Graziano F, Cascinu S. Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes' B colorectal cancer patients: how much evidence is enough? Ann Oncol 2003;14:1026-38.
34. Miller RT, Swanson PE, Wick MR. Fixation and epitope retrieval in diagnostic immunohistochemistry: a concise review with practical considerations. Appl Immunohistochem Mol Morphol 2000;8:228-35.
35. Johnston PG, Fisher ER, Rockette HE. Fisher B, Wolmark N, Drake JC et al. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 1994;12:2640-7.
36. Kim JH, Yoon SY, Kim C-N, Joo JH, Moon SK. Choe IS et al. The Bmi-1 oncoprotein is overexpressed in human colorectal cancer and correlates with the reduced p16INK4a/p14ARF proteins. Cancer Lett 2004; 203:217-24.
37. Hayes DF, Thor AD. c-erbB-2 in breast cancer: development of a clinically useful marker. Semin Oncol 2002;29:231-45.
38. Carrato A, Gallego J, Diaz-Rubio E. Oxaliplatin: results in colorectal carcinoma. Crit Rev Oncol Hematol 2002;44:29-44.
39. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN. Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004;22:1201-8.